Tag Archives: NASH

A New Drug for Diabetes and Fatty Liver Disease?

Posted on September 3, 2013 by Kristine Novak, PhD, Science Editor

Obeticholic acid (OCA)—an agonist of the farnesoid X receptor (FXR)— increases insulin sensitivity and reduces markers of liver inflammation and fibrosis in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD), according to a study published in … Continue reading →

Posted in GI Tract, Liver/Biliary, Pancreas, Technology | Tagged , , , , , , , , , , , , | 3 Comments

How Can the Gut Microbiota Contribute to Liver Disease?

Posted on July 8, 2013 by Kristine Novak, PhD, Science Editor

Microbes that reside in colons of obese individuals produce many compounds that could contribute to development of non-alcoholic fatty liver disease (NAFLD) and other complications of obesity, according to a study published in the July issue of Clinical Gastroenterology and … Continue reading →

Posted in GI Tract, Liver/Biliary | Tagged , , , , , , , , , , , | Leave a comment

How Common is Portal Hypertension in Patients With NAFLD?

Posted on August 27, 2012 by Kristine Novak, PhD, Science Editor

Patients with nonalcoholic fatty liver disease (NAFLD) are at risk for portal hypertension and esophageal varices, according to the September issue of Clinical Gastroenterology and Hepatology. The study also shows that factors such as advanced liver disease, type 2 diabetes, … Continue reading →

Posted in GI Tract, Liver/Biliary | Tagged , , , , , , , , , , | 5 Comments